Vanda Pharmaceuticals Inc. (NASDAQ: VNDA)’s stock price has decreased by -1.05 compared to its previous closing price of 4.75. However, the company has seen a 1.73% increase in its stock price over the last five trading sessions. PRNewsWire reported 2023-09-06 that WASHINGTON, Sept. 6, 2023 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the H.C.
Is It Worth Investing in Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) Right Now?
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) has a price-to-earnings ratio that is above its average at 18.29x. and a 36-month beta value of 0.71. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free
The average price predicted for Vanda Pharmaceuticals Inc. (VNDA) by analysts is $7.00, which is $2.3 above the current market price. The public float for VNDA is 55.19M, and at present, short sellers hold a 5.08% of that float. On September 18, 2023, the average trading volume of VNDA was 822.57K shares.
VNDA’s Market Performance
The stock of Vanda Pharmaceuticals Inc. (VNDA) has seen a 1.73% increase in the past week, with a -18.69% drop in the past month, and a -25.87% fall in the past quarter. The volatility ratio for the week is 4.35%, and the volatility levels for the past 30 days are at 4.66% for VNDA. The simple moving average for the past 20 days is -9.91% for VNDA’s stock, with a -30.12% simple moving average for the past 200 days.
Analysts’ Opinion of VNDA
Many brokerage firms have already submitted their reports for VNDA stocks, with Jefferies repeating the rating for VNDA by listing it as a “Hold.” The predicted price for VNDA in the upcoming period, according to Jefferies is $12 based on the research report published on February 25, 2022 of the previous year 2022.
VNDA Trading at -18.41% from the 50-Day Moving Average
After a stumble in the market that brought VNDA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.44% of loss for the given period.
Volatility was left at 4.66%, however, over the last 30 days, the volatility rate increased by 4.35%, as shares sank -19.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.46% lower at present.
During the last 5 trading sessions, VNDA rose by +1.73%, which changed the moving average for the period of 200-days by -54.32% in comparison to the 20-day moving average, which settled at $5.16. In addition, Vanda Pharmaceuticals Inc. saw -36.40% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VNDA starting from Wijkstrom Joakim, who sale 3,724 shares at the price of $5.84 back on Aug 21. After this action, Wijkstrom Joakim now owns 113,816 shares of Vanda Pharmaceuticals Inc., valued at $21,748 using the latest closing price.
Mitchell Stephen Ray, the Director of Vanda Pharmaceuticals Inc., sale 6,500 shares at $6.05 during a trade that took place back on Aug 10, which means that Mitchell Stephen Ray is holding 29,328 shares at $39,349 based on the most recent closing price.
Stock Fundamentals for VNDA
Current profitability levels for the company are sitting at:
- +2.49 for the present operating margin
- +89.86 for the gross margin
The net margin for Vanda Pharmaceuticals Inc. stands at +2.47. The total capital return value is set at 1.20, while invested capital returns managed to touch 1.19. Equity return is now at value 2.80, with 2.30 for asset returns.
Based on Vanda Pharmaceuticals Inc. (VNDA), the company’s capital structure generated 2.11 points at debt to equity in total, while total debt to capital is 2.07. Total debt to assets is 1.76, with long-term debt to equity ratio resting at 1.67. Finally, the long-term debt to capital ratio is 1.64.
When we switch over and look at the enterprise to sales, we see a ratio of -0.78, with the company’s debt to enterprise value settled at -0.32. The receivables turnover for the company is 7.71 and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.68.
Conclusion
To sum up, Vanda Pharmaceuticals Inc. (VNDA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
